New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Cisco Systems, Inc (NASDAQ:CSCO), Organovo Holdings Inc (NYSEMKT:ONVO), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Cytomedix, Inc (OTCMKTS:CMXI)
Cisco Systems, Inc (NASDAQ:CSCO) showed a volume of 44.53 million shares by the end of last trade whereas the average volume of the stock remained 49.78 million shares. The stock opened the session at $21.09 but then moved to $21.25. At that price, the stock showed a negative performance of -0.05%. Cisco Systems, Inc. (Cisco) designs, manufactures, and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry and provide services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and worldwide. Its products are designed to transform how people connect, communicate, and collaborate.
Will CSCO Get Buyers Even After The Recent Rally? Find Out Here
Organovo Holdings Inc (NYSEMKT:ONVO) opened the session at $9.24 and closed the session at $9.22. The stock showed a negative performance of -0.54% in previous trading session. Traded with volume of 2.81 million shares in the prior session and the average volume of the stock remained 8.21 million shares. Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
Has ONVO Found The Bottom And Ready To Gain Momentum? Find Out Here
Amarin Corporation plc (ADR) (NASDAQ:AMRN) opened the session at $1.97 and closed the session at $1.94. The stock showed a negative performance of -0.51% in previous trading session. Traded with volume of 6.47 million shares in the prior session and the average volume of the stock remained 6.68 million shares. The beta of the stock remained 1.08. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011,
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
Cytomedix, Inc (OTCMKTS:CMXI) the stock advanced 10.17% and finished the session at $0.650. Traded with volume of 520,021.00 shares in the prior session and the average volume of the stock remained 166,884.00 shares. The beta of the stock remained -0.19. Cytomedix, Inc. (Cytomedix) is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine.
Will CMXI Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)